Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Stopped: Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT Withdrawn before enrolling UNC Lineberger Comprehensive Cancer CenterNot specified NCT05937659
  2. Stopped: SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants Recruitment suspended University of ArizonaNot applicable NCT06177106
  3. Stopped: Multimedia Aid for Genetic Testing in Gynecologic Oncology Recruitment suspended UNC Lineberger Comprehensive Cancer CenterNot applicable NCT07084168
  4. Notable: IVMED-85 on Pediatric Myopia Enrollment reduced: 216 → 144 participants iVeena Delivery Systems, Inc.Phase 2 NCT05761795
  5. Notable: CRF2 Agonist · Worsening Heart Failure Enrollment reduced: 300 → 210 participants Corteria PharmaceuticalsPhase 2 NCT06815471
  6. Notable: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel · Prostate Cancer That Has Been Removed by Surgery Enrollment reduced: 612 → 175 participants NRG OncologyPhase 2/3 NCT03070886
  7. Notable: Improving Information Sharing Between Family Caregivers and Home Care Aides Enrollment reduced: 100 → 20 participants University of ConnecticutNot applicable NCT07227558
  8. Notable: Integrated Motivational Interviewing and Rational Emotive Behavior Therapy Intervention for Non-Suicidal Self-Injury Among Malaysian Primary School Students: A Feasibility Trial Protocol Enrollment reduced: 105 → 70 participants Universiti Utara MalaysiaNot applicable NCT07627061
  9. Notable: AI-Driven Multimodal Imaging Integration for Diagnosis and Prognostication of Digestive System Diseases Enrollment reduced: 5000 → 1000 participants First Affiliated Hospital, Sun Yat-Sen UniversityNot applicable NCT07087418
  10. Notable: Daraxonrasib and Daraxonrasib + GnP as First-line Treatment · Metastatic Pancreatic Adenocarcinoma Primary endpoint(s) modified Revolution Medicines, Inc.Phase 3 NCT07491445
  11. Notable: SCALE KIDS · Research Study to Look at How Well a New Medicine is at Lowering Weight · Obesity Results posted: Nov 16, 2026 Novo Nordisk A/SPhase 3 NCT04775082
  12. Notable: S243249 Monotherapy · Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation Start date pushed from Oct 20, 2026 to Feb 1, 2027 ServierPhase 1/2 NCT07722312
  13. Notable: MR-146 · Stage I and Stage II Neurotrophic Keratopathy Primary endpoint(s) modified Viatris Inc.Phase 1/2 NCT07923045
  14. Notable: TSN1611 Treating · Advanced Solid Tumors Harboring KRAS G12D Mutation Primary completion pushed from Oct 30, 2026 to Oct 30, 2027 Tyligand Pharmaceuticals (Suzhou) LimitedPhase 1/2 NCT06385925
  15. Notable: Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism Results posted: Nov 16, 2026 Boston Scientific CorporationPhase 4 NCT04790370
  16. Notable: CPU-YL01 Injection · Chronic Hepatitis B Primary endpoint(s) modified Jiangsu Chuangyuan Life Science and Technology Co., Ltd.Phase 1 NCT07918456
  17. Notable: UtiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy Primary and study completion dates pushed to Sep 30, 2027 Neuronostics LtdNot specified NCT06354868
  18. Notable: Feeding TL Trial Primary endpoint(s) modified University of FloridaPhase 2 NCT07919821
  19. Notable: RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer Recruitment opened University of Illinois ChicagoPhase 2 NCT07732634
  20. Notable: Precision Administration of Anti-thymocyte Globulin With or Without Verapamil Primary endpoint(s) modified University of FloridaPhase 2 NCT06455319
  21. Notable: Single-center Study of FAPI PET Imaging and Liquid Biopsy in Bladder Cancer Primary endpoint(s) modified Chiti ArturoPhase 2 NCT07257718
  22. Notable: Statin Combined With Amlodipine Treats Primary Aldosteronism Primary and study completion dates pushed to Nov 15, 2026 Third Military Medical UniversityPhase 4 NCT06523465
  23. Notable: Delivery and Effects of THC Vaping Liquids in the Bloodstream Primary completion pushed from Mar 1, 2028 to Dec 1, 2028 Roswell Park Cancer InstituteEarly Phase 1 NCT06334016
  24. Notable: Single-Dose Hyaluronic Acid Injection · Knee Osteoarthritis Primary endpoint(s) modified Fatih Sultan Mehmet Training and Research HospitalNot specified NCT07487038
  25. Notable: Impact of UFPs and MNPs on Fetal Health Primary endpoint(s) modified Alba Ruiz GaitánNot specified NCT07238608